Health and wellness company Rapid Nutrition plc (Euronext Growth Paris:ALRPD) announced on Tuesday that it has been chosen as a key partner in the Osteoarthritis Prevention Study (TOPS) led by Wake Forest University.
This project, receiving USD17.1m in funding from major health organisations, is the largest investigation into osteoarthritis prevention through weight loss and exercise in women. The five-year study, led by Wake Forest University's Department of Health and Exercise Science, aims to enrol 1,230 women aged 50 and above, focusing on those at risk of osteoarthritis due factors such as overweight status.
Rapid Nutrition's participation underscores its commitment to advancing scientific research and promoting women's health globally, the company said.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member